Novartis' potential "first-in-class" complement inhibitor reaches phase 2 clinical endpoint

Today, Novartis announced that its potential "first-in-class" oral factor B inhibitor iptacopan (LNP023) has reached its primary clinical endpoint in a phase 2 clinical trial for the treatment of patients with C3 glomerulopathy (C3G).

C3G is a rare and severe form of primary glomerulonephritis, which is characterized by complement disorders

Iptacopan is an oral specific alternative complement pathway factor B inhibitor

▲Factor B inhibitors can be used to treat a variety of complement-driven nephropathy (picture source: Novartis official website)

In this phase 2 clinical trial of two patient cohorts, C3G patients who had not yet received a kidney transplant had a 45% reduction in proteinuria level compared with baseline after 12 weeks of treatment with iptacopan (p=0.

In addition, both patient cohorts showed persistent and strong inhibition of alternative complement pathway activity

Reference materials:

[1] Novartis iptacopan meets primary endpoints in Phase II study in rare kidney disease C3 glomerulopathy (C3G).

(The original text has been deleted)